NEWTON, J., E. N. D. PALLADINO, C. WEIGEL, M. MACEYKA, M. H. GRALER, C. E. SENKAL, R. D. ENRIZ, Pavlína MARVANOVÁ, J. JAMPILEK, S. LIMA, S. MILSTIEN and S. SPIEGEL. Targeting defective sphingosine kinase 1 in Niemann?Pick type C disease with an activator mitigates cholesterol accumulation. Journal of Biological Chemistry. Bethesda, USA: Amer. Soc. Biochem. Mol. Biol., 2020, vol. 295, No 27, p. 9121-9133. ISSN 0021-9258. Available from: https://dx.doi.org/10.1074/jbc.RA120.012659.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Targeting defective sphingosine kinase 1 in Niemann?Pick type C disease with an activator mitigates cholesterol accumulation
Authors NEWTON, J., E. N. D. PALLADINO, C. WEIGEL, M. MACEYKA, M. H. GRALER, C. E. SENKAL, R. D. ENRIZ, Pavlína MARVANOVÁ (203 Czech Republic, belonging to the institution), J. JAMPILEK, S. LIMA, S. MILSTIEN and S. SPIEGEL.
Edition Journal of Biological Chemistry, Bethesda, USA, Amer. Soc. Biochem. Mol. Biol. 2020, 0021-9258.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.157
RIV identification code RIV/00216224:14160/20:00118106
Organization unit Faculty of Pharmacy
Doi http://dx.doi.org/10.1074/jbc.RA120.012659
UT WoS 000550698000020
Keywords in English sphingosine kinase; cholesterol; Niemann?Pick type C; sphingolipids; lysosomal storage disease; genetic disorder; lipid metabolism; neurodegeneration; sphingolipid; sphingosine kinase (SphK); sphingosine-1-phosphate (S1P); NPC1
Tags rivok, ÚChL
Tags International impact, Reviewed
Changed by Changed by: Mgr. Hana Hurtová, učo 244985. Changed: 24/2/2021 08:25.
Abstract
Niemann?Pick type C (NPC) disease is a lysosomal storage disorder arising from mutations in the cholesterol-trafficking protein NPC1 (95%) or NPC2 (5%). These mutations result in accumulation of low-density lipoprotein-derived cholesterol in late endosomes/lysosomes, disruption of endocytic trafficking, and stalled autophagic flux. Additionally, NPC disease results in sphingolipid accumulation, yet it is unique among the sphingolipidoses because of the absence of mutations in the enzymes responsible for sphingolipid degradation. In this work, we examined the cause for sphingosine and sphingolipid accumulation in multiple cellular models of NPC disease and observed that the activity of sphingosine kinase 1 (SphK1), one of the two isoenzymes that phosphorylate sphingoid bases, was markedly reduced in both NPC1 mutant and NPC1 knockout cells. Conversely, SphK1 inhibition with the isotype-specific inhibitor SK1-I in WT cells induced accumulation of cholesterol and reduced cholesterol esterification. Of note, a novel SphK1 activator (SK1-A) that we have characterized decreased sphingoid base and complex sphingolipid accumulation and ameliorated autophagic defects in both NPC1 mutant and NPC1 knockout cells. Remarkably, in these cells, SK1-A also reduced cholesterol accumulation and increased cholesterol ester formation. Our results indicate that a SphK1 activator rescues aberrant cholesterol and sphingolipid storage and trafficking in NPC1 mutant cells. These observations highlight a previously unknown link between SphK1 activity, NPC1, and cholesterol trafficking and metabolism.
PrintDisplayed: 21/7/2024 14:11